Skip to main content

Table 2 Clinic Characteristics of the Subjects

From: A stepwise data interpretation process for renal amyloidosis typing by LMD-MS

 

Training set

Validation set

Non-amyloid nephropathy

DN

FGN

IgAN

LN

MN

NAT

Age (years)

60.0 (52.0–64.0)

61.0 (51.8–67.3)

56.0 (51.0–60.0)

43.0 (39.0–46.8)

41.0 (31.0–42.0)

34.0 (29.0–38.0)

51.0 (45.0–56.0)

-

Gender (male/female)

22/20

31/19

6/7

2/6

3/6

0/5

12/3

5a

Upro (mg/day)

3482 (1731–7490)

3716 (2755–5687)

3835 (2658–8013)

3480 (2740–5340)

1060 (815–1690)

3583 (2142–6214)

3984 (3720–4248)

-

Alb (g/L)

22.9 (17.8–28.3)

25.7 (20.7–29.3)

27.4 (25.1–32.2)

31.8 (28.9–33.4)

38.8 (38.7–39.0)

26.2 (24.0–29.7)

16.8 (15.8–17.7)

-

Scr (μmol/L)

84.0 (58.0–141.0)

85.0 (68.5–100.0)

108.0 (60.0–191.0)

64.0 (57.0–99.0)

82.0 (67.0–92.0)

64.0 (59.0–68.0)

93 (85.5–100.5)

-

BUN (mmol/L)

6.0 (5.4–9.0)

7.3 (4.5–9.2)

5.4 (4.4–7.7)

4.7 (3.3–6.2)

5.6 (5.2–7.0)

5.4 (3.6–5.5)

5.0 (3.4–5.8)

-

  1. aClinical information of NAT specimen was not collected
  2. Data are presented as median with interquartile range
  3. Upro urine protein, Alb albumin, Scr serum creatinine, BUN blood urea nitrogen